Kura Oncology, Inc. (KURA) NASDAQ
8.94
-0.1(-1.11%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
8.94
-0.1(-1.11%)
Currency In USD
| Previous Close | 9.04 |
| Open | 9.08 |
| Day High | 9.2 |
| Day Low | 8.69 |
| 52-Week High | 12.49 |
| 52-Week Low | 5.45 |
| Volume | 1.14M |
| Average Volume | 1.62M |
| Market Cap | 793.2M |
| PE | -2.67 |
| EPS | -3.35 |
| Moving Average 50 Days | 9.16 |
| Moving Average 200 Days | 9.27 |
| Change | -0.1 |
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
GlobeNewswire Inc.
Feb 26, 2026 12:30 PM GMT
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and fu
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
GlobeNewswire Inc.
Jan 11, 2026 10:00 PM GMT
– Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net product revenue for the period from first commercial sale on November 21, 2025, through De
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
GlobeNewswire Inc.
Dec 08, 2025 3:30 PM GMT
– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and overall survival not yet reached in newly diagnosed N